Portfolio company
Paradigm Diagnostics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops genomic sequencing tests that provide oncologists with molecular profiling to guide personalised treatment decisions for patients with advanced cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Prevision Medicine
This company develops a live-cell testing platform that provides personalised drug response reports to help oncologists select effective treatments for cancer patients.
Foundation Medicine
This company develops genomic profiling tests to help doctors and researchers identify treatment options for cancer patients.
Delphi Diagnostics
This company develops genomic tests for breast cancer to assist clinicians and patients in personalising treatment decisions and predicting long-term survival outcomes.
Veracyte
This company develops genomic tests and diagnostic tools to help clinicians and patients make informed treatment decisions for various types of cancer.
Oxford Cancer Biomarkers
This company develops and commercialises precision diagnostic tests and digital pathology tools to help clinicians personalise cancer treatment and assess patient toxicity risks.
Astron Health
This company develops a precision oncology platform that provides molecular data analysis and personalised treatment reports for cancer patients and their clinicians.
4baseCare
This company develops genomic tests and AI-powered clinical decision support tools for oncologists, hospitals, and pharmaceutical researchers to personalise cancer treatment.
Prevision Medicine
This company develops functional drug sensitivity tests to help oncologists select personalized cancer treatments for patients using live cell analysis.